0001104659-21-069880.txt : 20210520 0001104659-21-069880.hdr.sgml : 20210520 20210520160602 ACCESSION NUMBER: 0001104659-21-069880 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20210518 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210520 DATE AS OF CHANGE: 20210520 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IOVANCE BIOTHERAPEUTICS, INC. CENTRAL INDEX KEY: 0001425205 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 753254381 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36860 FILM NUMBER: 21944512 BUSINESS ADDRESS: STREET 1: 999 SKYWAY ROAD STREET 2: SUITE 150 CITY: SAN CARLOS STATE: CA ZIP: 94070 BUSINESS PHONE: 6502607120 MAIL ADDRESS: STREET 1: 999 SKYWAY ROAD STREET 2: SUITE 150 CITY: SAN CARLOS STATE: CA ZIP: 94070 FORMER COMPANY: FORMER CONFORMED NAME: Lion Biotechnologies, Inc. DATE OF NAME CHANGE: 20131015 FORMER COMPANY: FORMER CONFORMED NAME: Genesis Biopharma, Inc DATE OF NAME CHANGE: 20100319 FORMER COMPANY: FORMER CONFORMED NAME: FREIGHT MANAGEMENT CORP DATE OF NAME CHANGE: 20080128 8-K 1 tm2117109d1_8k.htm FORM 8-K
0001425205 false 0001425205 2021-05-18 2021-05-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K
Current Report

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (date of earliest event reported): May 18, 2021

 

IOVANCE BIOTHERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Charter)

 

Delaware
(State of Incorporation)
 
001-36860   75-3254381
Commission File Number   (I.R.S. Employer Identification No.)
     
999 Skyway Road, Suite 150    
San Carlos, California   94070
(Address of Principal Executive Offices)   (Zip Code)
     
(650) 260-7120
(Registrant’s Telephone Number, Including Area Code)
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Common stock, par value $0.000041666 per share IOVA The Nasdaq Stock Market, LLC

 

 

 

 

 

 

Item 8.01. Other Events.  

 

On May 18, 2021, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release providing a regulatory update for its lifileucel potency assays. The full text of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

On May 19, 2021, the Company issued a press release announcing clinical data updates for lifileucel in advanced melanoma at the upcoming American Society of Clinical Oncology 2021 Annual Meeting. The full text of the press release is attached hereto as Exhibit 99.2 and incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.  

 

  (d) Exhibits.  

 

Exhibit
No.		   Description
99.1   Press Release of Iovance Biotherapeutics, Inc., dated May 18, 2021.
99.2   Press Release of Iovance Biotherapeutics, Inc., dated May 19, 2021.
104   Cover Page Interactive Data File - the cover page interactive date file does not appear in the Interactive Date File because its XBRL tags are embedded within the Inline XBRL document.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: May 20, 2021 IOVANCE BIOTHERAPEUTICS, INC.  
     
     
  By: /s/ Frederick G. Vogt
    Frederick G. Vogt, General Counsel

 

 

 

 EX-99.1 2 tm2117109d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

 

 

Iovance Biotherapeutics Provides Regulatory Update for Lifileucel Potency Assays

 

SAN CARLOS, Calif., May 18, 2021 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced receipt of regulatory feedback from the U.S. Food and Drug Administration (FDA) regarding its potency assays for lifileucel. Previously, the company reported the submission of assay data to the FDA and recently the FDA provided comments regarding the data package.

 

Following FDA feedback, Iovance will continue its ongoing work developing and validating its potency assays and plans to submit additional assay data and to meet with the FDA in the second half of 2021. The company's biologics license application (BLA) submission for lifileucel is now expected to occur during the first half of 2022.

 

“TIL is a first-in-class, one-time administration cell therapy and the first potential BLA for a cell therapy in solid tumors,” stated Maria Fardis, Ph.D., MBA, Iovance President and Chief Executive Officer. “As such, TIL product is complex by nature and alignment with FDA on a potency assay is an important step toward BLA submission. With a regenerative medicines advanced therapy (RMAT) designation for lifileucel, FDA recognizes the unmet need for patients with metastatic melanoma who progress after anti-PD1 therapy.”

 

About Iovance Biotherapeutics, Inc.

 

Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient’s own immune cells to attack cancer. TIL cells are extracted from a patient’s own tumor tissue, expanded through a proprietary process, and infused back into the patient. Upon infusion, TIL reach tumor tissue, where they attack cancer cells. The company has completed dosing in pivotal programs in patients with metastatic melanoma and cervical cancer. In addition, the company’s TIL therapy is being investigated in a registration-supporting study for the treatment of patients with locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC). Clinical studies are also underway to evaluate TIL in earlier stage cancers in combination with currently approved treatments, and to investigate Iovance peripheral blood lymphocyte (PBL) T cell therapy for blood cancers. For more information, please visit www.iovance.com.

 

 

 

 

Forward-Looking Statements

 

Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). All such written or oral statements made in this press release, other than statements of historical fact, are forward-looking statements and are intended to be covered by the safe harbor for forward-looking statements provided by the PSLRA. Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the effects of the COVID-19 pandemic; risks related to the timing of and our ability to successfully develop, submit, obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, our product candidates, and our ability to successfully commercialize any product candidates for which we obtain FDA approval; preliminary and interim clinical results, which may include efficacy and safety results, from ongoing clinical trials may not be reflected in the final analyses of our ongoing clinical trials or subgroups within these trials; the risk that enrollment may need to be adjusted for our trials and cohorts within those trials based on FDA and other regulatory agency input; the new version of the protocol which further defines the patient population to include more advanced patients in our cervical cancer trial may have an adverse effect on the results reported to date; the risk that we may be required to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from the FDA or other regulatory authorities; the risk that our interpretation of the results of our clinical trials or communications with the FDA may differ from the interpretation of such results or communications by the FDA; the acceptance by the market of our product candidates and their potential reimbursement by payors, if approved; our ability or inability to manufacture our therapies using third party manufacturers or our own facility may adversely affect our potential commercial launch; the results of clinical trials with collaborators using different manufacturing processes may not be reflected in our sponsored trials; the risk that unanticipated expenses may decrease our estimated cash balances and increase our estimated capital requirements; and other factors, including general economic conditions and regulatory developments, not within our control.

 

CONTACTS

 

Iovance Biotherapeutics, Inc:

Sara Pellegrino, IRC

Vice President, Investor Relations & Public Relations

650-260-7120 ext. 264

Sara.Pellegrino@iovance.com

 

Solebury Trout:

Zara Lockshin

646.378.2960

zlockshin@soleburytrout.com

 

 

 

 EX-99.2 3 tm2117109d1_ex99-2.htm EXHIBIT 99.2

Exhibit 99.2

 

 

 

Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel

in Advanced Melanoma at Upcoming ASCO 2021 Annual Meeting

 

86% Overall Response Rate (ORR) for Lifileucel in Combination with Pembrolizumab in Immune Checkpoint Inhibitor (ICI) Naïve Advanced Melanoma Patients in IOV-COM-202 Clinical Study

 

At Median of 28-Month Study Follow up, Median Duration of Response (DOR) not reached in Cohort 2 in post-PD1 Advanced Melanoma in C-144-01 Study; Data Support Use of Lifileucel Following Earlier Detection of Progression on Anti-PD-1 Therapy

 

Additional Data Updates at ASCO 2021 Meeting

 

SAN CARLOS, Calif., May 19, 2021 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced additional clinical data for lifileucel alone and in combination with pembrolizumab in patients with advanced melanoma. The data are available in two ASCO abstracts, with additional updates to be provided at the upcoming ASCO 2021 Annual Meeting, to be held June 4-8, 2021.

 

Maria Fardis, Ph.D., President and Chief Executive Officer of Iovance Biotherapeutics, stated, “We are very excited that our latest clinical datasets demonstrate the broad potential for lifileucel in advanced melanoma. For the first time we are reporting results for lifileucel as an earlier treatment for advanced melanoma in combination with pembrolizumab, demonstrating an overall response rate (ORR) of 86% in patients who are naïve to anti-PD-1 therapy. We are impressed with the results for this combination regimen, particularly since pembrolizumab alone demonstrated a 33% ORR in a comparable patient population. In addition, in a post-PD1 advanced melanoma patient population in Cohort 2 in the C-144-01 study, shorter duration of prior anti-PD-1 therapy maximizes Duration of Response (DOR) to lifileucel treatment.”

 

Lifileucel in Combination with Pembrolizumab in Advanced Melanoma (IOV-COM-202 Study)

Early data suggest the response rate of lifileucel plus pembrolizumab may be additive in patients with immune checkpoint inhibitor (ICI)-naïve advanced melanoma. Cohort 1A in the IOV-COM-202 study is evaluating lifileucel in combination with pembrolizumab in up to 12 patients who are naïve to ICI, or anti-PD-1, therapy. Six of the initial seven patients had a confirmed objective response, representing an 86% ORR (1 Complete Response (CR) and 5 Partial Responses (PR), with one best response of stable disease (abstract data extraction: February 2021). The longest duration of response was 16.8 months.

 

The Treatment-Emergent Adverse Event (TEAE) profile was consistent with the underlying disease and known Adverse Event (AE) profiles of pembrolizumab, NMA-LD and IL-2. These encouraging data confirm the potential feasibility and activity of lifileucel in combination with pembrolizumab in early-line treatment of patients with advanced melanoma. Updated results for the initial seven patients will be available in the upcoming ASCO poster.

 

 

 

 

Lifileucel Following anti-PD-1 therapy in Advanced Melanoma (C-144-01 clinical study)

As previously reported, the long-term follow-up data for Cohort 2 in the C-144-01 clinical study continue to demonstrate durability and depth of lifileucel TIL therapy response. DOR was not reached at 28.1 months of median study follow up and ORR remained at 36.4 percent.

 

New data in the ASCO abstract suggest that DOR was positively associated with shorter cumulative duration of prior anti-PD-1 therapy. In responders, the median cumulative duration and median prior lines of anti-PD-1 therapy was 4.4 months (range: 1.4-22.5 months) and 1.5 lines (range: 1-4). These results support earlier use of lifileucel following anti-PD-1 therapy instead of retreatment with anti-PD-1 based - regimens.

 

All patients in Cohort 2 had high baseline disease burden and were heavily pretreated (3.3 mean prior therapies), including anti-PD1 and BRAF/MEK inhibitors if BRAFV600 mutation positive. The adverse event profile was consistent with the underlying advanced disease, lymphodepletion and IL-2 regimens, with no new adverse events emerging over time. Updated results for Cohort 2 with longer duration of follow up will be part of the oral presentation during ASCO 2021.

 

Iovance Presentation and Poster at ASCO 2021

 

Title: Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy.

Authors: James M. G. Larkin, et al.

Session Title: Melanoma/Skin Cancers

Session Type: Oral Abstract Session

Abstract Number: 9505

Location: ASCO Meeting Library at https://meetinglibrary.asco.org/ and https://www.iovance.com/our-science/publications/

Session Date and Time: Sunday, June 6, 2021 from 8:00 – 11:00 a.m. ET

 

Title: Safety and efficacy of lifileucel (LN-144), an autologous, tumor infiltrating lymphocyte cell therapy in combination with pembrolizumab for immune checkpoint inhibitor naïve patients with advanced melanoma.

Authors: Sajeve Samuel Thomas, et al.

Session Title: Melanoma/Skin Cancers

Session Type: ePoster Session

Abstract Number: 9537

Location: ASCO Meeting Library at https://meetinglibrary.asco.org/ and https://www.iovance.com/our-science/publications/

ePoster Viewing: on demand beginning Friday, June 4, 2021 at 9:00 a.m. ET

 

About Iovance Biotherapeutics, Inc.

 

Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient’s own immune cells to attack cancer. TIL cells are extracted from a patient’s own tumor tissue, expanded through a proprietary process, and infused back into the patient. Upon infusion, TIL reach tumor tissue, where they attack cancer cells. The company has completed dosing in pivotal programs in patients with metastatic melanoma and cervical cancer. In addition, the company’s TIL therapy is being investigated in a registration-supporting study for the treatment of patients with locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC). Clinical studies are also underway to evaluate TIL in earlier stage cancers in combination with currently approved treatments, and to investigate Iovance peripheral blood lymphocyte (PBL) T cell therapy for blood cancers. For more information, please visit www.iovance.com.

 

 

 

 

Forward-Looking Statements

 

Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). All such written or oral statements made in this press release, other than statements of historical fact, are forward-looking statements and are intended to be covered by the safe harbor for forward-looking statements provided by the PSLRA. Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the effects of the COVID-19 pandemic; risks related to the timing of and our ability to successfully develop, submit, obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, our product candidates, and our ability to successfully commercialize any product candidates for which we obtain FDA approval; preliminary and interim clinical results, which may include efficacy and safety results, from ongoing clinical trials may not be reflected in the final analyses of our ongoing clinical trials or subgroups within these trials; the risk that enrollment may need to be adjusted for our trials and cohorts within those trials based on FDA and other regulatory agency input; the new version of the protocol which further defines the patient population to include more advanced patients in our cervical cancer trial may have an adverse effect on the results reported to date; the risk that we may be required to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from the FDA or other regulatory authorities; the risk that our interpretation of the results of our clinical trials or communications with the FDA may differ from the interpretation of such results or communications by the FDA; the acceptance by the market of our product candidates and their potential reimbursement by payors, if approved; our ability or inability to manufacture our therapies using third party manufacturers or our own facility may adversely affect our potential commercial launch; the results of clinical trials with collaborators using different manufacturing processes may not be reflected in our sponsored trials; the risk that unanticipated expenses may decrease our estimated cash balances and increase our estimated capital requirements; and other factors, including general economic conditions and regulatory developments, not within our control.

 

CONTACTS

 

Iovance Biotherapeutics, Inc:

Sara Pellegrino, IRC

Vice President, Investor Relations & Public Relations

650-260-7120 ext. 264

Sara.Pellegrino@iovance.com

 

Solebury Trout:

Zara Lockshin

646.378.2960

zlockshin@soleburytrout.com

 

 

 

 EX-101.SCH 4 iova-20210518.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 iova-20210518_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 iova-20210518_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 tm2117109d1_ex99-1img001.jpg GRAPHIC begin 644 tm2117109d1_ex99-1img001.jpg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end GRAPHIC 8 tm2117109d1_ex99-2img001.jpg GRAPHIC begin 644 tm2117109d1_ex99-2img001.jpg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end XML 9 tm2117109d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001425205 2021-05-18 2021-05-18 iso4217:USD shares iso4217:USD shares 0001425205 false 8-K 2021-05-18 IOVANCE BIOTHERAPEUTICS, INC. DE 001-36860 75-3254381 999 Skyway Road Suite 150 San Carlos CA 94070 650 260-7120 false false false false false Common stock, par value $0.000041666 per share IOVA NASDAQ XML 10 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Cover
May 18, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 18, 2021
Entity File Number 001-36860
Entity Registrant Name IOVANCE BIOTHERAPEUTICS, INC.
Entity Central Index Key 0001425205
Entity Tax Identification Number 75-3254381
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 999 Skyway Road
Entity Address, Address Line Two Suite 150
Entity Address, City or Town San Carlos
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94070
City Area Code 650
Local Phone Number 260-7120
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.000041666 per share
Trading Symbol IOVA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false

EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://lbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2117109d1_8k.htm iova-20210518.xsd iova-20210518_lab.xml iova-20210518_pre.xml tm2117109d1_ex99-1.htm tm2117109d1_ex99-2.htm http://xbrl.sec.gov/dei/2021 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2117109d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2117109d1_8k.htm" ] }, "labelLink": { "local": [ "iova-20210518_lab.xml" ] }, "presentationLink": { "local": [ "iova-20210518_pre.xml" ] }, "schema": { "local": [ "iova-20210518.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "iova", "nsuri": "http://lbio.com/20210518", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2117109d1_8k.htm", "contextRef": "From2021-05-18to2021-05-18", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://lbio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2117109d1_8k.htm", "contextRef": "From2021-05-18to2021-05-18", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lbio.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 17 0001104659-21-069880-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-069880-xbrl.zip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end